$13.67 0.2 1.3%
| Market Cap | £322.2m |
| Enterprise Value | £322.2m |
| Revenue | £n/a |
| Position in Universe | th / 6850 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
CM Life Sciences II Inc. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company is engaged in pursuing an initial business combination target in any industry, sector or geographic region. It intends to focus on the life sciences sector. The Company neither engages in any business operations nor generates any revenues.
| Last Annual | December 31st, 2020 |
| Last Interim | January 1st, 1970 |
| Incorporated | December 15, 2020 |
| Public Since | February 23, 2021 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Financials |
| Industry | Holding Companies |
| Index | |
| Exchange | NASDAQ Capital Market (Dual Listing) |
| Shares in Issue | 32,600,000 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 667 Madison Avenue, NEW YORK, 10065, United States |
| Web | |
| Phone | +1 212 4746724 |
| Auditors | WithumSmith Brown PC |
